PDF(Pubmed)
Abstract：
OBJECTIVE: There is very little literature reporting the association of matrix metalloproteinase-1 (MMP1) with personal susceptibility to bladder cancer. In the current study, we carried out the first examination of the contribution of MMP1 rs1799750 to bladder cancer risk in Taiwanese.
METHODS: A total of 375 bladder cancer cases and 375 healthy controls were genotyped for MMP1 rs1799750 via polymerase chain reaction-restriction fragment length polymorphism methodology and this was evaluated for association with clinicopathological factors.
RESULTS: The frequencies of MMP1 rs1799750 2G/2G, 1G/2G, and 1G/1G genotypes were 35.7%, 44.8% and 19.5% in the group with bladder cancer and 32.5%, 46.4%, and 21.1% in the healthy control group (p for trend=0.6362). The odds ratios (ORs) for bladder cancer risk after adjusting for age and gender for those carrying 1G/2G and 1G/1G genotypes at MMP1 rs1799750 were 0.88 (95% CI=0.62-1.24, p=0.4357) and 0.83 (95% CI=0.61-1.26, p=0.3990), respectively, compared with the wild-type 2G/2G genotype. In allelic frequency analysis, the adjusted OR for those carrying the 1G allele at MMP1 rs1799750 was 0.87 (95% CI=0.71-1.23, p=0.3479) compared to those people carrying a 2G allele.
CONCLUSIONS: Our findings indicated that the genotypes at MMP1 rs1799750 appear to play little role in determining personal susceptibility to bladder cancer for Taiwanese.
METHODS: A total of 375 bladder cancer cases and 375 healthy controls were genotyped for MMP1 rs1799750 via polymerase chain reaction-restriction fragment length polymorphism methodology and this was evaluated for association with clinicopathological factors.
RESULTS: The frequencies of MMP1 rs1799750 2G/2G, 1G/2G, and 1G/1G genotypes were 35.7%, 44.8% and 19.5% in the group with bladder cancer and 32.5%, 46.4%, and 21.1% in the healthy control group (p for trend=0.6362). The odds ratios (ORs) for bladder cancer risk after adjusting for age and gender for those carrying 1G/2G and 1G/1G genotypes at MMP1 rs1799750 were 0.88 (95% CI=0.62-1.24, p=0.4357) and 0.83 (95% CI=0.61-1.26, p=0.3990), respectively, compared with the wild-type 2G/2G genotype. In allelic frequency analysis, the adjusted OR for those carrying the 1G allele at MMP1 rs1799750 was 0.87 (95% CI=0.71-1.23, p=0.3479) compared to those people carrying a 2G allele.
CONCLUSIONS: Our findings indicated that the genotypes at MMP1 rs1799750 appear to play little role in determining personal susceptibility to bladder cancer for Taiwanese.
摘要：
目的：很少有文献报道基质金属蛋白酶-1（MMP1）与膀胱癌个人易感性的关系。在目前的研究中,我们首次检查了MMP1rs1799750对台湾人膀胱癌风险的影响.
方法：通过聚合酶链反应-限制性片段长度多态性方法对375例膀胱癌和375例健康对照进行MMP1rs1799750基因分型，并评估其与临床病理因素的关系。
结果：MMP1rs17997502G/2G的频率，1G/2G,1G/1G基因型占35.7%，膀胱癌组分别为44.8%和19.5%和32.5%,46.4%,健康对照组为21.1%(趋势p=0.6362)。在调整MMP1rs1799750中携带1G/2G和1G/1G基因型的人的年龄和性别后，膀胱癌风险的比值比（OR）为0.88（95％CI=0.62-1.24，p=0.4357）和0.83（95％CI=0.61-1.26，p=0.3990），分别,与野生型2G/2G基因型相比。在等位基因频率分析中，与携带2G等位基因的人群相比,在MMP1rs1799750处携带1G等位基因的人群的校正OR为0.87(95%CI=0.71-1.23,p=0.3479).
结论：我们的研究结果表明，MMP1rs1799750的基因型似乎在确定台湾人对膀胱癌的个人易感性中几乎没有作用。
方法：通过聚合酶链反应-限制性片段长度多态性方法对375例膀胱癌和375例健康对照进行MMP1rs1799750基因分型，并评估其与临床病理因素的关系。
结果：MMP1rs17997502G/2G的频率，1G/2G,1G/1G基因型占35.7%，膀胱癌组分别为44.8%和19.5%和32.5%,46.4%,健康对照组为21.1%(趋势p=0.6362)。在调整MMP1rs1799750中携带1G/2G和1G/1G基因型的人的年龄和性别后，膀胱癌风险的比值比（OR）为0.88（95％CI=0.62-1.24，p=0.4357）和0.83（95％CI=0.61-1.26，p=0.3990），分别,与野生型2G/2G基因型相比。在等位基因频率分析中，与携带2G等位基因的人群相比,在MMP1rs1799750处携带1G等位基因的人群的校正OR为0.87(95%CI=0.71-1.23,p=0.3479).
结论：我们的研究结果表明，MMP1rs1799750的基因型似乎在确定台湾人对膀胱癌的个人易感性中几乎没有作用。
